Sanofi chooses Meeker to head Genzyme unit; FDA approves Lundbeck seizure drug Onfi;

> Six months into its integration of Genzyme, Sanofi ($SNY) tapped Genzyme's COO, David Meeker, to take the helm there. He will report to Sanofi chief Christopher Viehbacher. Item

> Lundbeck got the FDA nod for Onfi, its therapy for a severe form of epilepsy known as Lennox-Gastaut Syndrome. News

> Strong growth in the U.S. helped India's Dr. Reddy's Laboratories make up for slow sales in its domestic market and post forecast-beating profits for its fiscal second quarter. Report

> A Chinese manufacturer of veterinary medicines sued Pfizer's ($PFE) animal health division after the U.S.-based company stopped selling its 3-Nitro product for safety reasons. Article

> Companies' disregard of the Association of the British Pharmaceutical Industry's communications code is a growing problem, a U.K. compliance expert said. Story

And Finally... Human papillomavirus, already linked to several types of cancer, may also increase the risk of heart disease, a new study suggests. News

Suggested Articles

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

Pfizer, GSK, BIO and others are all planning vaccine messages for fall.